Category

Glioblastoma (“GBM”)

VBI Vaccines Announces Poster Presentation at the 7th International Congenital CMV Conference & 17th International CMV Workshop

By | Conferences, Cytomegalovirus ("CMV"), Glioblastoma ("GBM"), Press Releases
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that David Anderson, Ph.D., Chief Scientific Officer, will present the poster, “CMV gB/pp65 eVLPs Formulated with GM-CSF as a Therapeutic Vaccine...
Read More

VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO)

By | Conferences, Glioblastoma ("GBM"), Press Releases
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced that initial clinical data from the Phase 1/2a study of VBI-1901 in recurrent Glioblastoma (GBM) patients will be presented in a...
Read More

VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards

By | Cytomegalovirus ("CMV"), Glioblastoma ("GBM"), Press Releases, Sci-B-Vac®
VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the formation of three Scientific and Clinical Advisory Boards (SABs) consisting of leading experts in infectious disease and immuno-oncology research and vaccine...
Read More

VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients

By | Glioblastoma ("GBM"), Press Releases
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modification Intermediate-dose study arm: enrollment complete Initial immunologic data from low and intermediate-dose cohorts expected in the fourth quarter 2018 VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage...
Read More

VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients

By | Glioblastoma ("GBM"), Press Releases
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modification Low-dose study arm: enrollment complete Intermediate-dose study arm: enrollment commenced VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology...
Read More